Loading...
Loading...
Puma Biotechnology, Inc.
, a development stage biopharmaceutical
company, announced that interim results from an ongoing Phase II clinical
trial of Puma's investigational drug PB272 (neratinib) were presented at the
2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is currently
taking place in San Antonio, Texas. The trial was supported by the National
Comprehensive Cancer Network®, ASCO's Young Investigator Award, Susan G. Komen
for the Cure®, and the Terri Brodeur Breast Cancer Foundation. The
presentation is further detailed below.
The trial was conducted as a Phase I/II trial of PB272 given in combination
with the anticancer drug temsirolimus in patients with HER2-positive
metastatic breast cancer. The Phase I portion of the trial, which was reported
previously, determined that the maximum tolerated dose was 240 mg of neratinib
daily with 8 mg of temsirolimus weekly and the dose limiting toxicity was
diarrhea. The Phase II portion of the study was conducted in two cohorts. The
first cohort, referred to as the Maximum Tolerated Dose (MTD) cohort, received
240 mg of neratinib daily with 8 mg of temsirolimus weekly. This cohort of
patients received low dose loperamide (4 mg per day) prophylactically in order
to reduce the neratinib related diarrhea. The second cohort of patients,
referred to as the Dose Escalation cohort (DE cohort), received 240 mg of
neratinib daily and initially received 8 mg of temsirolimus weekly. This
cohort of patients received high dose loperamide (16 mg per day initially)
prophylactically in order to reduce the neratinib related diarrhea. If
patients in the DE cohort had no tolerability issues with the combination of
neratinib and temsirolimus given at 8 mg per week during the first cycle of
treatment, patients in this DE cohort were allowed to dose escalate the
temsirolimus to 15 mg per week for the remainder of the study. Patients in
both cohorts in the study received a median of 3 prior regimens in the
metastatic setting (range 1-8 prior regimens) before entering the trial. The
37 patients in the MTD cohort were enrolled at 3 centers in the United States
and the 45 patients in the DE cohort were enrolled at 8 centers in the United
States, Europe and Asia.
The interim safety results of the study showed that the most frequently
observed adverse event for the patients who received the combination of
neratinib plus temsirolimus was diarrhea. For the 37 patients in the MTD
cohort, who received low dose loperamide prophylactically, 12 patients (32%)
experienced grade 3 diarrhea. For the 41 patients in the DE cohort, who
received high dose loperamide prophylactically and were allowed to dose
escalate the temsirolimus dose, 7 patients (17%) reported grade 3 diarrhea. 4
(57%) of the 7 patients in the DE cohort who experienced grade 3 diarrhea were
not compliant with the high dose loperamide prophylaxis. There are 4 patients
in the DE cohort who did not yet have safety data reported and are therefore
not included in the safety population. For the patients in the DE cohort, thus
far 47% of the patients have been able to dose escalate from 8 mg per week of
temsirolimus to 15 mg per week of temsirolimus.
The interim efficacy results from the trial showed that for the 37 patients in
the MTD cohort, 11 patients (30%) experienced a partial response (PR). The
median duration of response for this cohort of patients was 3.0 months and the
median progression free survival was 4.8 months. For the 37 evaluable patients
in the DE cohort, the efficacy results from the trial demonstrated that 11
patients (30%) experienced a partial response (PR). The median duration of
response for this cohort of patients was 7.4 months and the median progression
free survival is not yet mature. There are a total of 18 patients currently on
active treatment in the trial. 8 of the 17 active patients in the DE cohort
have not yet had tumor assessments.
Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology,
said, "We continue to be pleased with the data on the combination of PB272
with temsirolimus. This interim data continues to demonstrate strong antitumor
activity in a heavily pretreated population and compares favorably to what
would typically be seen for other treatment options for patients in this
setting. We look forward to following the remaining patients on study to
completion of the trial and advancing the combination of PB272 and
temsirolimus into Phase III trials in 2015."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in